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AdenocarcinomaAbstract Background: Pleural malignancies disturb normal ways of protein metabolism deferring
imbalance of backside markers in body tissues and fluids and see the sights of muscle and protein
derangement.
Purpose: The aim of this work to study markers of protein depletion and muscle catabolism in
cases with malignant pleural effusion.
Patients and methods: Thirty patients with malignant pleural effusions not under chemotherapy
were studied regarding markers of muscle and protein derangement (plasma albumin & potassium
levels and creatinine height index) and radiological signs (the presence of pleural thickness by com-
puted tomography (CT) of chest and muscle wasting by skeletal muscle ultrasound) plus thoraco-
scopic findings (plaques and adhesions).
Results: Metastatic adenocarcinoma accounted for a higher percentage in smoking 66%, aging
(59.06 ± 13.04) and duration of illness (13.13 ± 4.85) than other pleural malignancies. In the same
way metastatic adenocarcinoma showed the major type in hypoalbuminemia, hypokalemia and CT
pleural thickening than other malignancies (11.11%, 72.22% and 77.76% in that order). However,
malignant lymphoma was prevalent in echographic features of muscle wasting, pleural plaques and
pleural adhesions (66.7% for each marker). Lastly, squamous cell carcinoma prevailed in creatinine
highest index than the previous three tumors (75%). Nevertheless, there were no statistical signifi-
cant differences between the four diagnosed malignancies except for pleural plaques that were sig-
nificant (p= 0.03).
Conclusion: Pleural malignancy can enhance the body decomposition in particular muscular
components and hastens protein catabolism with the help of feasible laboratory and radiological
markers.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).nsoura,
oo.com
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Malignant pleural effusions are common clinical dilemma in
patients with neoplastic disease. In one postmortem series,
malignant effusions were found in 15% of patients who passed
away with malignancies [1]. Every now and then, there has
been an increasing recognition of the clinical importance of
patients’ general health and in specific; muscle mass catabolism
as part of the cancer cachexia syndrome, and its impact has
been evaluated in a wide range of malignancies including
pleuropulmonary, breast, gastrointestinal, hepatocellular and
colorectal cancers [2–6]. The term sarcopenia is characterized
by a triad of progressive loss of skeletal muscle mass, muscle
strength and physical performance [7]. This loss of muscle
mass is not necessarily linked with significant or sudden weight
loss. There are several mechanisms that may be involved in the
onset and evolution of sarcopenia, among them are, protein
synthesis, proteolysis, neuromuscular integrity and muscle fat
content. Recognizing these mechanisms and their underlying
causes is expected to facilitate the design of intervention trials
that target one or further underlying mechanisms [8]. Interest
in sarcopenia as a poor prognostic marker in cancer is rising;
in various populations with cancer sarcopenia is associated
with poorer performance status, [2] reduced overall survival
[9,10] and increased risk of chemotherapy toxicities [3,5]. The
hallmark of sarcopenia is low muscle mass, more specifically
an appendicular skeletal muscle mass [11]. While many differ-
ent techniques have been used to measure muscle mass and
strength, a few have been included into routine assessment of
the cancer population. The current gold standards are CT
Computed tomography, magnetic resonance imaging MRI
and dual-energy X-ray absorptiometry (DEXA) scans. CT
and MRI allow precise discrimination between fat and other
soft tissue including muscle and are therefore investigations
of choice [12]. Muscle ultrasound is a convenient technique
to visualize normal and pathological muscle tissues as it is
non-invasive and real-time [13]. More indirect techniques for
measuring muscle mass comprise bioelectrical impedance anal-
ysis which is non-invasive but less accurate compared with
DEXA. It includes a measure of organ mass other than skele-
tal muscle in addition it is easily performed in clinical settings
[14]. Measurements of mid-upper arm circumference and arm
muscle area using skin fold thickness methods have also been
used [15], although these assessments are less accurate and they
exists considerable inter-observer and intra-observer variabil-
ity. Measurements of muscle strength in the literature have
mainly centered around handgrip strength (HGS) and quadri-
ceps strength, although in non-cancer elderly patients, func-
tional assessments such as the Short Physical Performance
Battery and sit-to-stand tests [16,17] have been shown to
correlate with adverse outcomes. If the loss of muscle mass and
strength have significant clinical suggestion for patients with
cancer, then standardized, validated diagnostic thresholds are
clearly needed. The aim of this work was to study the markers
of protein depletion and muscle catabolism in cases with
malignant pleural effusion.
Patients and methods
A prospective clinical study was conducted on thirty patients
proved to have malignant pleural effusions with medical thora-coscopy on admission to Chest medicine department Man-
soura University Hospitals during the period from June 2014
to August 2015. They did not receive chemotherapy yet, they
were studied for markers of muscle and protein depletion.
Anthropometric measurements were excluded due to the sub-
jective variability, plus age-related changes in fat deposits
and loss of skin elasticity contribute to errors of estimation
in older people. Age of the patient and duration of illness (in
months) were considered. They underwent the subsequent
laboratory investigations (plasma albumin& potassium levels,
creatinine height index; CHI = (24 h urine creatinine  100)/
(expected 24 h urine creatinine for height).
Creatinine height index  consider Protein depletion = if
the patient CHI < 80%.
Hypokalemia = if the patient plasma level < 3.5 mEq/L.
Hypoalbuminemia = if the patient plasma level < 2.5 g/
dL [18].
Also, radiological signs as presence of pleural thickness on
computed chest tomography (CT chest) as defined by Downer
et al., as [19] thickening of pleura, more than 5 mm with com-
bined area of involvement more than 25% of chest wall if bilat-
eral and 50% involvement if unilateral may be focal or diffuse.
and signs of muscle wasting with the help of skeletal muscle
ultrasound and thoracoscopic findings of plaques and adhe-
sions that define the state of body anabolism and deposition
of fibrin and elastin.
Exclusion criteria:
(1) Extreme of age >65 years and <18 years.
(2) Debilitating diseases (chronic liver and renal failure,
uncontrolled DM, blood diseases, known other
malignancy).
(3) Neuromuscular diseases (Duchene disease, myopathy,
myasthenia, motor neuron disease and poliomyelitis).
(4) Diseases and drugs causing hypokalemia (dieuretics,
digitalis, chronic diarrhea, Cushing disease and renal
failure).
(5) Diseases and drugs causing Hypoalbuminemia (liver cir-
rhosis, protein losing nephropathy and protein losing
enteropathy).
Procedures
Methods
Prethoracoscopy assessment
For each patient, the following were reviewed: (1) detailed
medical history, (2) investigations done to reach the final diag-
nosis including; chest radiographs and chest-CTs, and medical
thoracoscopic pleural biopsy.
Thoracoscopy procedure
Thoracoscopic maneuver was done under local anesthesia with
spontaneous breathing and light sedation (midazolam, fen-
tanyl) by an experienced pulmonologist in the endoscopy
room. Patients were located in lateral decubitus position, with
the implicated side raised upward. After skin sterilization,
small skin incision was done with blunt dissection to enter
the pleural space between the third and sixth intercostal
space, along the midaxillary line. A rigid thoracoscope
Table 2 Diagnosed cases by medical thoracoscopy of studied
population.
Pathological diagnosis Number & percent
Metastatic Adenocarcinoma 18 (60%)
Malignant lymphoma 6 (20%)
Squamous cell carcinoma 4 (13.33%)
Malignant mesothelioma 2 (6.6%)
Total 30 (100%)
Pleural Carnal Attrition 423(Karl Storez-Germany) was popped in, and the pleural cavity
was visualized. The parietal, visceral and diaphragmatic pleu-
rae were consecutively inspected and any pathological lesions
were described and identified as well as the mediastinal vessels
and lymph nodes were inspected followed by multiple parietal
and visceral pleural biopsies sampling under direct visual con-
trol. All thoracoscopic pleural biopsies were stained by hema-
toxylin and eosin and examined by expert pathologist to
diagnose the histopathological type of lesions. An intercostal
tube was inserted before wound closure. Chest radiographs
were routinely obtained after the procedure and daily there-
after until chest tube removal. Once the lung had expanded
and intercostal tube output had decreased to less than 50 ml
per 24 h, chest tube was removed.
Skeletal muscle ultrasound
transcutaneous ultrasonography was conducted on thirty
patients on both; muscles of the upper limb (biceps muscle)
and lower limb (quadriceps muscle) bilaterally with the aid
of Philips HD 5; superficial two dimensional probe 7–
11 MHz for assessment of echographic signs of wasting (high
degree of tissue histogram, presence of fibrosis, low degree of
vascularity by Doppler study and reduction of muscle mass)
by longitudinal and transverse sectors handling of the muscles.
Statistical analysis
Data were analyzed using SPSS (Statistical Package for Social
Sciences) version 21. Qualitative data were presented as num-
ber and percentage. Quantitative data were presented for nor-
mality by Kolmogorov–Smirnov test. Normally distributed
data were presented as mean and standard deviation. Compar-
ison between groups was done using Chi-square test. Student t-
test and one way ANNOVA test were used to compare
between two groups. p value < 0.05 was considered
significant.
Results
Table 1 demonstrates that our study was conducted on
30 patients (17 male and 13 female) with a mean age of
55.33 ± 12.8.
Table 2 illustrates that the finally diagnosed cases in this
study were metastatic adenocarcinoma 60% and malignant
lymphoma 20% while squamous cell carcinoma showed
13.33% and lastly malignant mesothelioma accounted for
6.6%.
Table 3 identifies that sex difference affected the markers of
muscle wasting and protein derangement. Males were higher in
percentage in the occasion of all marker than females, they
were more elder than female but with less duration of illness.Table 1 Age and sex demography of studied population.
Frequency Percent
Studies cases Female 13 43.3
Male 17 56.7
Total 30 100.0
Age Mean ± SD
55.33 ± 12.8Significant statistical differences were present in smoking and
age of cases between both sexes only.
Table 4 and Fig. 1 presented below shows that metastatic
adenocarcinoma accounted for a higher percentage in smoking
66%, aging (59.06 ± 13.04) and duration of illness
(13.13 ± 4.85) than other pleural malignancies. In the same
way metastatic adenocarcinoma showed the major type in
hypoalbuminemia, hypokalemia and CT pleural thickening
than other malignancies (11.11%, 72.22% and 77.76% in that
order). However, malignant lymphoma was prevalent in echo-
graphic features of muscle wasting, pleural plaques and pleural
adhesions (66.7% for each marker). Lastly, squamous cell car-
cinoma prevailed in creatinine highest index than the previous
three tumors (75%). Nevertheless, there were no statistical sig-
nificant differences between the four diagnosed malignancies
except for pleural plaques that were significant (p= 0.03).
Discussion
Although malignant neoplasm from the first impression takes
the mind into a closed circuit of catabolic derangement of the
body tissues and somatic attrition, the degree of this catabo-
lism depends on various factors and initiators for instance,
the initial body built, the presence or absence of any debilitat-
ing diseases, the type of neoplasm, and the presence or absence
of tissue secondaries. Our study draws attention about the
impact of malignant pleural effusion on the muscle catabolism
and protein derangement via assessment of more simple
applicable and accessible clinical and radiological markers.
Sarcopenia; loss of muscle mass; as part of a weight-losing
syndrome, is a central feature of cancer cachexia. This implies
that consideration of both muscle mass and function, rather
than weight loss alone, is clinically important. Understanding
this relationship, and the factors associated with each, provide
opportunities for focused intervention to improve clinical out-
comes. While studies exploring molecular and metabolic fac-
tors associated with the loss of muscle mass have contributed
to a better understanding of the pathophysiology of cancer
cachexia, there remains considerable uncertainty in relation
to mechanisms [20].
Our study showed that sex difference affected the markers
of muscle wasting and protein derangement. Males were higher
in percentage in presenting all markers than females, they were
more elder than females but with less duration of illness.
Significant statistical differences were present in smoking and
age only. Many studies found that those with cachexia and/
or weight loss also had coexistent loss of muscle mass with
characteristic gender disparity [21–23]. Three studies explored
the loss of muscle mass comparing men and women, finding
that a significantly greater percentage of men were affected,
Table 3 Markers of muscle and protein derangement in both genders:-.
Smoking Age
(years)
Duration of
illness (months)
Low creatinine
height index
Hypoalbuminemia Hypokalemia Muscle wasting
By ultrasound
Pleural thickening
By CT chest
Pleural plaques
By MT
Pleural Adhesions
By MT
Male (17) 16 (94.11%) 57.12 ± 14.23 10.9 ± 4.28 11 (64.7%) 2 (11.76%) 13 (76.5%) 10 (58.8%) 13 (76.5%) 3 (17.6%) 6 (35.3%)
Female (13) 1 (7.7%) 53 ± 6.76 13.4 ± 5.6 6 (46.15%) 0 (0%) 6 (46.15%) 5 (38.5%) 8 (61.5%) 4 (30.7%) 3 (23.07%)
p value 0.000 0.04 0.139 0.149 0.313 0.093 0.213 0.314 0.340 0.377
*MT: medical thoracoscopy, *CT: computed tomography.
Table 4 Markers of muscle and protein derangement in diagnosed cases.
Pleural malignancy Markers
Smoking Age (years) Duration of
illness (months)
Low creatinine
height index
Hypoalbuminemia Hypokalemia Muscle wasting
by ultrasound
Pleural thickening
by CT chest
Pleural plaques
By MT
Pleural adhesion
by MT
Malignant lymphoma 3 (50%) 47.5 ± 12.09 11.66 ± 4.27 3 (50%) 0 4 (66.7%) 4 (66.7%) 4 (66.7%) 4 (66.7%) 4 (66.7%)
Malignant mesothelioma 1 (50%) 47.5 ± 13.43 1.87 ± 0.59 1 (50%) 0 1 (50%) 1 (50%) 2 (100%) 0 0
Metastatic Adeno-carcinoma 11 (61.11%) 59.06 ± 13.04 13.13 ± 4.85 10 (55.55%) 2 (11.11%) 13 (72.22%) 10 (55.55%) 14 (77.77%) 2 (11.11%) 3 (16.66%)
Squamous cell carcinoma 2 (50%) 54.25 ± 8.5 12.31 ± 5.67 3 (75%) 0 1 (25%) 0 1 (25%) 1 (25%) 2 (50%)
p value 0.98 0.859 0.960 0.750 0.699 0.344 0.18 0.15 0.03 0.07
*MT: medical thoracoscopy, *CT: computed tomography.
4
2
4
A
.M
.
A
b
u
m
o
ssa
la
m
et
a
l.
Figure 1 Graph shows markers of protein and muscle catabolism in malignant pleural effusion.
Pleural Carnal Attrition 425and that they exhibited a decreasing trend in fat free mass
(FFM) especially after chemotherapy compared with baseline
that was excluded in this work, whereas women did not.
Reflecting the process of loss of muscle mass in the different
stages of cancer, a study of 60 patients with preoperative non-
small cell lung cancer (NSCLC) with stage I and II disease
showed no difference in FFM compared with controls [24],
whereas in a cohort of 352 patients with advanced cancer,
84% of those with cachexia had a reduced FFM [25].
Metastatic adenocarcinoma accounted for a higher percent-
age in smoking 66%, aging (59.06 ± 13.04) and duration of ill-
ness (13.13 ± 4.85) than other pleural malignancies.
Adenocarcinoma is strongly related to smoking as stated by
many old and recent studies. Prolonged duration of this type
of malignancy either primary or secondary may be related to
the hidden nature of adenocarcinoma either of pulmonary or
extrapulmonary origin that is usually discovered by the occur-
rence of multiple secondaries as first presentation, also not to
omit the role of inflammatory cytokines that preclude to more
protein deletion in this malignancy.
In the same way metastatic adenocarcinoma predominated
in hypoalbuminemia, hypokalemia that attributed to the
higher catabolic process and increased oxidative stress associ-
ated with and subsequent effects of cellular lysis especially with
chemotherapy given. Regarding CT pleural thickening, unlike
other researches that confirmed the strong association of visu-
alizing nodules and or masses in adenocarcinoma as declared
also by Jiang et al. [26] who stated that; the endoscopic find-
ings of malignant pleural effusion mostly showed nodules of
varying sizes. The nodules could be grape-like, cauliflower-
like, fused into masses, or diffused small nodules and the main
pathological diagnosis of malignant pleural effusion was pleu-
ral metastases (37.8% of cases). In our research pleural thick-
ness could be certified due to associated inflammatory exudatesdue to long standing condition due to prolonged duration of
illness. Nonetheless, malignant lymphoma was prevalent in
echographic features of muscle wasting, pleural plaques and
pleural adhesions (66.7% for each marker). As known, lym-
phoma is infrequently detected in pleural space until it attain
large size that can be identified via histopatology, hence its sys-
temic impact could be the main insult in anorexia, hyper-
catabolic state leading to more wasting and more protein
breakdown. Lastly, squamous cell carcinoma prevailed in cre-
atinine highest index than the previous three tumors (75%),
owing to the higher rate of cavitation and tissue breakdown.
The pathophysiology of loss of muscle mass in patients with
lung cancer is complex, as illustrated in the diversity of articles
exploring this. Low protein enclosure has been associated with
low albumin and high acute phase protein concentrations
[27,22,28], reflecting the inflammatory pathways involved.
Abnormal protein metabolism is implicated in the develop-
ment of sarcopenia; however, neither anabolic nor proteolytic
pathways had any consistent effect on the loss of muscle mass
[29].
It also highlights the difficulty in making comparisons
between all accessible studies, due to the heterogeneity of
methods employed in measuring muscle mass and different
variables used for defining sarcopenia. The relevance of this
definition to patients with cancer is debatable, for a number
of reasons. First, sarcopenia manifests in patients with can-
cer of all ages and is not isolated to the elderly alone. Sec-
ond, the pathophysiology of sarcopenia in patients with
cancer may differ at least in part to that of the non-cancer
elderly population [30]. This constraint also means that some
articles included in this review, while being relevant to sar-
copenia, were more broadly related to muscle mass outcomes
in lung cancer cachexia, rather than assessing sarcopenia
directly.
426 A.M. Abumossalam et al.In an honest concise talk, our study lacked three points; the
first was assessment of the laboratory tissue markers of muscle
derangement that are variable and numerous but the sensitiv-
ity and specificity of each of them were under area of debate
and costly in practice, the second was the requirement in eval-
uating other pleural tumor that may clarify the proposed rea-
sons for this catabolic process but actually those were the
commonest pleural malignancy in our geographic area hence
multicenter study needs to be conducted all over our country,
Egypt for truthful conclusion. Lastly our study was applied to
a small number of patients but in fact those patients were fit
for medical thoracoscopy and accepted fulfilling the research
without discomfort with obtainable consent hence we are in
need for more large studies to be conducted in this era in the
future.
Conclusions
Pleural malignancy represents a foremost pointer of a subter-
ranean debility, reflecting the pervasive nature and the pooped
sequels of this disorder. Nevertheless assessment of the level of
body derangement needs more and more tools, hence empha-
sizing on the need of tissue, body fluid on the same direction as
creatinine height index and radiological markers as seen as
muscle echography for the estimation of its substitute.Conﬂict of interests
There is no conflict of interests in this study.References
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